<DOC>
	<DOCNO>NCT01517295</DOCNO>
	<brief_summary>Objective evaluate pharmacokinetics profile hydrocodone 's metabolite hydromorphone patient take hydrocodone routine basis 3 month chronic pain correlate hydromorphone level hydrocodone usage .</brief_summary>
	<brief_title>Pharmacokinetic Study Hydrocodone/APAP Chronic Pain Patients</brief_title>
	<detailed_description>Hydrocodone combination commonly prescribe pain medication United States . All current available Hydrocodone formulation short act Acetaminophen/Ibuprofen . Chronic pain patient take pain medication extend time overload Acetaminophen serious concern liver failure excessive concurrent alcohol use . Also current hydrocodone combination available U.S. short act provide pain relief 3-6 hr . Hydromorphone metabolite Hydrocodone play significant role provide pain relief patient . Although long act extend release hydrocodone formulation FDA approve time , day extend release Hydromorphone ( ER ) approve FDA currently market name Exalgo Â® . PK study chronic hydrocodone/acetaminophen usage important determine equivalent potency hydromorphone ER , clinician use simple conversion formula switch hydromorphone ER . Although medical professional use Opiate conversion formula regular basis Opioid rotation , publish study show pharmacokinetic data patient take hydrocodone chronic pain . Our goal use PK data guide clinician data use extend release hydromorphone chronic pain management provide predictable pain relief minimize acetaminophen usage .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Hydromorphone</mesh_term>
	<mesh_term>Hydrocodone</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Man woman age 1875 Documented clinical diagnosis chronic pain . Have take hydrocodone/APAP chronic noncancer pain . Subjects currently hydrocodone/APAP must take minimal daily dose 15mg Hydrocodone least 30 day . Subjects must sign informed consent document indicate understand purpose procedure require study willing participate study . Subjects take concomitant medication Nutraceuticals interfere Hydrocodone metabolism list Appendix 11 and/or deem clinically significant pharmacovigilance team contract monitor advise . Health concern study physician feel may confound study result . Individuals cognitively impair able give inform consent . Previous participation clinical research trial within 30 day prior randomization . The subject ongoing abuse illicit substance , alcohol , actively smoke marijuana .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Hydromorphone</keyword>
	<keyword>Hydrocodone</keyword>
	<keyword>APAP</keyword>
</DOC>